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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use
of varenicline for smoking-cessation therapy creates or increases depression in patients without
existing depressive illness.
STUDY DESIGN: Review of two randomized controlled trials published in 2011 and one
observational cohort study published in 2009, all English language.
DATA SOURCES: Two randomized, double-blind, controlled clinical trials comparing
varenicline to placebo in smoking cessation, and one observational cohort study comparing
varenicline use within subjects. All articles were found using PubMed and EBSCO.
OUTCOMES MEASURED: Changes in depression was evaluated using the MontgomeryÅsberg Depression Rating Scale (MADRS), and adverse events were recorded and classified into
depression-related according to the Medical Dictionary for Regulatory Activities version 12 and,
in the observational cohort study, the British Drug Safety Research Unit standards.
RESULTS: Bollinger et al. and Garza et al. demonstrated a present but nonsignificant increase in
depressive adverse events associated with varenicline use. Garza et al. reported a similarly small
and nonsignificant worsening in MADRS score in the varenicline arm. Kasliwal et al. reported a
nonsignificant change in depressive adverse events.
CONCLUSIONS: Results of the three studies show that there is inconclusive evidence regarding
a link between varenicline and new-onset depression in smoking cessation. None of the studies
demonstrated any significant relationship between varenicline and depression or depressive
adverse events, but limitations in study design prevent the results from convincingly addressing
such a relationship. The results encourage further studies designed both to assess varenicline’s
relationship with depression and to account for the varenicline’s higher quit rate as a possible
source of depressive changes.
KEY WORDS: varenicline, depression, randomized, adverse
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INTRODUCTION
Smoking is a prominent risk factor for a wide variety of pathologies, and remains a
common component of patient social histories. The addictive nature of smoking renders
smoking cessation difficult for most patients, and drug-assisted methods are increasingly being
considered in the quitting process.5 One such drug, varenicline, can be effective but remains
controversial due to concerns of depression-related adverse effects.13
An estimated 45.3 million U.S. adults smoke cigarettes—about 19.3% of the U.S.
population greater than 18 years of age.6 While smoking-related health care visits have proven
too numerous to track reliably, smoking-attributable deaths in the U.S. average approximately
443,000 per year.5 Because of cigarette smoking’s combination of systemic effects and addictive
pharmacodynamics, annual health-related economic losses in the U.S. are estimated at $193
billion—more than 10% of total U.S. annual healthcare expenditures.5 Cost estimates are not
limited to the macro-scale; one longitudinal analysis considered health-care costs, opportunity
costs and other assorted factors, and estimated an effective per-pack cost to regular smokers of
almost $40.15 Smoking cessation with varenicline typically costs between $50 and $192 per
month, with a typical regimen lasting 3 months.7
Smoking addiction has been principally traced to the agonistic effects of nicotine on
nicotinic acetylcholine receptors, which preferentially release dopamine in the central nervous
system. As with other addictive dopaminergic compounds (e.g., cocaine, opiates), this reinforces
addictive behavior and, with dependence, causes withdrawal symptoms when absent. Recent
studies have demonstrated evidence of addiction within only weeks of smoking and, in some
individuals, within only days.8 Withdrawal symptoms stem from nicotine-induced downregulation of dopamine and other neurotransmitters, the deficiency of which can cause headache,
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anxiety, nausea, dysphoria, depression, paresthesias, and intense cravings. Beyond its neurologic
effects, cigarette smoking produces profound deleterious changes elsewhere in the body.
Carcinogenic effects increase rates of lung cancer, along with cancers of the mouth, larynx,
pharynx, sinuses, esophagus, liver, pancreas, stomach, kidney, bladder, cervix, bowel, and blood.
Increases in blood viscosity exacerbate ischemic disease. Breathing allergies are aggravated, and
smoking can create or worsen obstructive pulmonary disease.
Smoking cessation is a significant and difficult process; the majority of smokers indicate
they would like to quit, about 36% make an annual attempt to quit, and only 3% successfully
remain smoking-abstinent after six months.13 Traditional strategies for smoking-cessation have
generally been unassisted: self-imposed abrupt cessation (“cold turkey”) or gradual cessation
(“weaning”), or assisted: group therapy, psychosocial therapy, or long-term counseling. More
recently developed assisted strategies utilize pharmacotherapy, with the hope of improving on
the poor long-term quit rates of traditional efforts. Drug-assisted strategies fall into two
categories: nicotine-replacement therapy (NRT), and psychoactive therapy. NRT has shown
some efficacy coupled with a low adverse-event profile, but its long-term efficacy has proven
questionable.1 The two mainstays of psychoactive therapy are bupropion SR—an atypical
antidepressant—and varenicline—a nicotine receptor partial agonist. Both medications have
demonstrated improved efficacy over both traditional methods and NRT, but epidemiological
surveillance and case reports have raised concerns regarding neuropsychiatric adverse events; the
U.S. Food and Drug Administration (FDA) has issued a Black Box Warning of neuropsychiatric
symptoms and suicidality for both drugs.3,13 Varenicline has been shown to have the highest
efficacy of smoking cessation options, but depression and suicide may be very serious side
effects of the drug—especially in patients with no prior history of depressive illness, who may
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suffer dangerous depressive symptoms before they are identified by the patient or healthcare
provider.3,4 This selective evidence-based medicine review evaluated two randomized, placebocontrolled, double-blind studies and one observational cohort study to examine the depressive
adverse effects of varenicline in smoking cessation.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not the use of
varenicline for smoking-cessation therapy creates or increases depression in patients without
existing depressive illness.
METHODS
The population chosen adult smokers ≥ 18 years of age, with the RCTs further selecting
subjects that smoked an average of 10+ cigarettes a day during the previous year, with no period
of abstinence greater than 3 months. The intervention studied in the RCTs was varenicline in its
standardized dosing schedule: 0.5 mg QD for 3 days, followed with 0.5 mg BID for 4 days,
followed by 1 mg BID for 11 weeks. The observational cohort study reported the majority but
not entirety of subjects using the standardized dosing schedule. For the RCTs, comparisons were
made between varenicline and visually-matched placebo of identical dosage and schedule.
Measured outcomes that are being utilized were neuropsychiatric adverse events (AEs) of a
depressive type—including suicide attempt—and changes in depressive mood index.
Key words used in the searches were “varenicline,” “depression,” “randomized,” and
“adverse.” All articles were published in peer-reviewed journals and in the English language.
The author searched the articles through PubMed and EBSCO, and selected articles based on
relevance to the clinical question and inclusion of patient-oriented outcomes (suicide, depressivetype AEs, or worsened index of depression). Inclusion criteria consisted of studies where design
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was either prospective or randomized, double-blind, placebo-controlled, studies that included
patient-oriented outcomes, and studies of adult smokers > 18 years of age. Exclusion criteria
consisted of studies with exclusively disease-oriented outcomes, studies that did not track
adverse event data independent of efficacy data, and studies of smokers < 18 years of age. The
statistics reported in the studies included mean change from baseline, 95% confidence interval
(CI), and p-value.
OUTCOMES MEASURED
Outcomes measured were based on a psychiatric index of depression and incidence of
reported AEs. The index utilized was the Montgomery-Åsberg Depression Rating Scale
(MADRS).12 The MADRS measures depressed mood using a 10-item list, with each item having
a range of 0 (least severe) to 6 (most severe). Each item assesses a different aspect of
depression: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite,
concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts.
AE reporting was coded and categorized based on the Medical Dictionary for Regulatory
Activities version 12 and, in the observational cohort study, the British Drug Safety Research
Unit standards.
RESULTS
The two randomized, controlled trials in this review compared varenicline to placebo, and
the observational cohort study compared varenicline within-subjects at 1-month intervals.
The study by Bollinger et al. was a randomized placebo-controlled study that included 593
participants randomized into two intervention arms, of which 492 completed the study (83%).
394 subjects were assigned to the varenicline arm, with 336 completing (85%), and 199 subjects
were assigned to the placebo arm, with 156 completing (78%). Duration of follow-up was 16
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Table 1 - Demographics & Characteristics of included studies
Study
Type
Pts.
Age
Inclusion
Exclusion
(n)
Criteria
Criteria
DoubleWomen of
Adult
smokers
Bollinger blind RCT 593 18–75
childbearing age that
(18–75
y/o)
et al.
y/o
refused birth control
with BMI 15–
2
(2011)
methods during the
38, weight of
45.5+ kg, that
smoked an
average of 10+
cigarettes/day
during the
previous year
and with no
period of
abstinence > 3
months.

study; any current or
past history of
psychiatric illness
including present or
past suicidal
behavior, ideation or
attempts; severe
unstable medical
condition; past
history of varenicline
use; concurrent use
of smoking cessation
medications;
concurrent
enrollment in other
clinical trials

W/D

Interventions

101

Varenicline;
dosage
schedule: 0.5
mg q.d. x 3
days, then 0.5
mg b.i.d. x 4
days, then 1 mg
b.i.d. x 11
weeks

Garza et
al. (2011)

Doubleblind RCT

110

18–75
y/o

Adult smokers
(18–75 y/o) that
smoked an
average of 10+
cigarettes/day
during the
previous year
and with no
period of
abstinence > 3
months

Women of
childbearing age that
refused birth control
methods during the
study; any current or
past history of
psychiatric illness
including present or
past suicidal
behavior, ideation or
attempts; severe
unstable medical
condition; past
history of varenicline
use; concurrent use
of smoking cessation
medications;
concurrent
enrollment in other
clinical trials

22

Varenicline;
dosage
schedule: 0.5
mg q.d. x 3
days, then 0.5
mg b.i.d. x 4
days, then 1 mg
b.i.d. x 11
weeks

Kasliwal
et al.
(2009) 10

Prospective
cohort
study

2682

> 18
y/o

Adult smokers
part of the
English
National Health
Service (NHS)

None

117

Varenicline;
dosage
schedules not
consistently
specified;
73.6% of
subjects clearly
reported the
standard 1 mg
b.i.d. dosing

9
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weeks, with adverse events (AEs) recorded up to 30 days after the administration of the last dose
of the intervention. For purposes of this review, AEs were treated as the sum of AE categories
“Depressed mood disorders or disturbances” and “Suicidal and self-injurious behaviors.” No
statistical significance in AE incidence was found between the varenicline and placebo groups (p
> .05). Table 2 shows incidence of depressive AEs, where there was a small but nonsignificant
difference of AE incidence in the varenicline group (36%) compared to the placebo group (35%).
The relative risk increase (RRI) was calculated to be 57.1% and absolute risk increase (ARR)
was 0.1%. Numbers needed to harm (NNH) was calculated as 1,000, meaning 1,000 patients
need to be treated with varenicline for 1 patient to suffer an additional depressive AE.
Table 2: Incidence of depressive adverse events
CER
EER
RRI
ARI
35%
36%
2.9%
0.1%

NNH
1,000

P
> .05

The study by Garza et al. was a randomized placebo-controlled study that included 110
participants randomized into two intervention arms, of which 88 completed the study (80%). 55
subjects were assigned to the varenicline arm, with 39 completing (71%), and 55 subjects were
assigned to the placebo arm, with 49 completing (89%). Duration of follow-up was 16 weeks,
with additional follow-up conducted for subjects categorized as “lost to follow-up” in the
original study duration. While a “worst-case” analysis was not done on all subjects lost to
follow-up, the additional post-study follow-up determined that AEs accounted for only 3 of the
16 subjects lost in the varenicline group. Changes in depressive mood were measured by
deviation from baseline MADRS scores for the varenicline group (LS mean ± SE: 1.52 ± .21)
and placebo group (LS mean ± SE: 1.50 ≠ .28), as shown in table 3. No significant difference
was found between the two arms (difference = .03, 95% CI —.68–.73; p > .05). For purposes of
this review, adverse events were treated as the AE category “Depressed mood disorders or
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disturbances;” no suicidal events were reported. No significance in AE incidence was found
between the varenicline and placebo groups (p > .05). Table 4 shows incidence of depressive
AEs, where there was a small but nonsignificant difference of AE incidence in the varenicline
group (11%) compared to the placebo group (9.1%). The relative risk increase (RRI) was
calculated to be 21% and absolute risk increase (ARI) was 1.9%. Numbers needed to harm was
calculated as 52, meaning 52 patients need to be treated with varenicline for 1 patient to suffer an
additional depressive AE.
Table 3: Change from baseline MADRS total score (LS mean ± SE)
Placebo
Varenicline
Difference
1.50 ± .28
1.52 ± .21
0.03 (95% CI —.68–.73)
Table 4: Incidence of depressive adverse events
CER
EER
RRI
ARI
9.1%
11%
21%
1.9%

NNH
52

P
> .05

P
> .05

The study by Kasliwal et al. was the initial report of an ongoing observational cohort study
of 2,682 patients in the British National Health Service (NHS). While the study utilizes ongoing
monthly questionnaires, the data reported represent the 4 months following the first prescription
of varenicline for each given patient. For the purposes of this review, 44 patients with a
significant psychiatric past medical history (PMH) are excluded, and so the population of
consideration is 2,638. The 4-month incidence of depressive adverse events was 15 (0.57%), and
of suicidal ideation was 1 (0.04%). After accounting for the aforementioned exclusion, no
suicidal events were reported. Though the study was not designed or powered for betweengroups comparison, a recent study of overall depression rates within the NHS found a mean 4month incidence of combined depressive symptoms and depression diagnoses of 0.83%.14 While
no protective effect of varenicline is presumed, the incidence of depression in the study’s
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population was lower than the mean incidence of a larger NHS sample, as seen in table 5.

Table 5: Incidence of depressive symptoms
Kasliwal et al. 10
(n=2,638)
Mean 4-month
0.57%
Incidence

Rait et al. 14
(n=2,982,024)
0.83%

Difference
—0.26%

DISCUSSION
This literature review investigated the possibility that the use of varenicline for smoking
cessation therapy might create or worsen depression in patients without known depressive
illness. The studies by Bollinger et al. and Garza et al. were randomized, controlled trials that
failed to find a significant difference in new-onset depression between subjects taking
varenicline and those taking placebo. The study by Kasliwal et al. established reports of newonset depressive symptoms, but at a rate that was lower than an NHS mean for a similar time
span.
Limitations were present in each study that affect their validity regarding the question of
concern. Kasliwal et al. utilized a large cohort size but by the observational nature of the study
design, no significant causal links can be drawn between varenicline and depression. Indeed, the
results of that study might seem to indicate a protective effect of varenicline, but such a
conclusion would be subject to significant sampling bias given the breadth of the NHS sample
for depression incidence (e.g., the broader NHS data account for all patients in the sample
population, not only those engaged in smoking-cessation therapy). That study is further limited
by the collection of data as reliant upon General Practitioner submission, adding both another
possible sampling bias to the consideration and inconsistent/missing values from some
questionnaires that “diluted” the overall data set.
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Both Bollinger et al. and Garza et al. acknowledged financial support by Pfizer, Inc., the
U.S. marketer of the Chantix® brand of varenicline. Bollinger et al. also acknowledged that
their study was principally powered for efficacy analysis, limiting the extent of significance that
could be established for adverse events reported. Similarly, while the study by Garza et al. was
specifically designed to assess neuropsychiatric AEs, its lack of a predefined hypothesis
prevented the application of more rigorous statistical comparisons (e.g., t-test, ANOVA,
ANCOVA). Garza et al. also note that their study population was restricted to smokers willing
and able to commit to a 2-week inpatient period, which raises the concern of sampling bias and
reduced external validity.
Perhaps most importantly, no studies yet published—including those in this review—have
adequately addressed two key points: 1) Smoking cessation itself is understood to be a possible
aggravating factor in depression or suicide.11 If there is an increased link between varenicline
and depression, is it a direct consequence of the drug’s pharmacology or a statistical
consequence of the drug’s efficacy? In other words, do more varenicline patients become
depressed because more of them successfully quit smoking? 2) While new-onset depression is
an undesirable POEM by itself, suicide is both a worse outcome and a rarer one. Even in
Kasliwal et al., a large sample size (n=2,682) yielded only 6 suicide-related events, of which 5
were in patients with PMH significant for psychiatric illness. Tracking such an outcome
properly requires either a significant sample size or a series of RCTs—powered to assess suicide
rate differences—that could be collapsed across a meta-analysis.
CONCLUSION
The studies reviewed collectively are inconclusive regarding varenicline’s influence on
new-onset depression. While the lack of significance found in the comparisons by Garza et al.
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and Bollinger et al. point toward a lack of causal link between varenicline and depression,
limitations both in the design and implementation of those studies prevent that conclusion from
being firmly supported. Likewise, the study by Kasliwal et al. suffers limitations in design that,
without strong evidence from either other study, hinder its use in conclusively proving or
disproving a causal link between varenicline and new-onset depression.
More-substantial clinical research has established a link between varenicline and adverse
neuropsychiatric outcomes other than depression, and varenicline continues to carry an FDA
Black Box warning.13 Further, there is stronger evidence of a deleterious effect of varenicline
when used by patients with existing depressive illness. While this literature review indicates no
significant association between varenicline and depressive events, it does not reliably rule out
that such an association exists. Cantrell et al. and others recommend that varenicline remain a
second-line treatment option, and further suggest that some form of depression screening should
be administered to all patients prior to varenicline use.
Ideally, future research into varenicline’s safety will focus on two points. First, if there is
a difference in depressive events with varenicline use, is it due directly to the drug’s
neuropsychiatric effects or its improved quit rate? Second, does careful screening and proactive
mental health management improve outcomes for patients taking varenicline? Until both
questions are addressed with greater confidence, varenicline may have an uncertain role in
modern smoking cessation therapy.
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